Genelux Corporation
GNLXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 21, 2025 | Maxim Group | $20.00(+200%) | $6.67 | TheFly | |
| Oct 21, 2025 | Lake Street | Chad Messer | $16.00(+152%) | $6.35 | TheFly |
| Oct 21, 2025 | Loop Capital Markets | Chad Messer | $16.00(+152%) | $6.35 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Benchmark | maintain | Speculative Buy | Mar 20, 2026 |
| Benchmark | maintain | Speculative Buy | May 8, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 31, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 25, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 15, 2024 |
| Benchmark | maintain | Speculative Buy | Jun 3, 2024 |
| Benchmark | maintain | Speculative Buy | May 31, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 13, 2024 |
| Benchmark | maintain | Speculative Buy | Apr 3, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 2, 2024 |
| Benchmark | maintain | Speculative Buy | Nov 24, 2023 |
| Benchmark | maintain | Speculative Buy | Jun 9, 2023 |
| Brookline Capital | maintain | Hold | May 18, 2023 |
| Benchmark | maintain | Speculative Buy →Buy | Feb 15, 2023 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-0.20| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.21 | $-0.20 | — | — |
| May 7, 2026 | $-0.20 | $-0.18 | — | — |
| Mar 19, 2026 | $-0.24 | $-0.22 | $8.0K | $8.0K |
| Nov 5, 2025 | $-0.21 | $-0.23 | — | — |
| Aug 7, 2025 | $-0.20 | $-0.22 | — | — |
| May 6, 2025 | $-0.21 | $-0.24 | — | — |
| Mar 28, 2025 | $-0.26 | $-0.17 | $452.0K | — |
| Nov 14, 2024 | $-0.19 | $-0.19 | — | — |
News
Genelux (NASDAQ: GNLX - Get Free Report) and Protagonist Therapeutics (NASDAQ: PTGX - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership. Valuation and Earnings This table compares Genelux and Protagonist
-- A platinum-relapsed SCLC patient achieved 16.7 months progression-free survival following Olvi-Vec and platinum rechallenge, exceeding the PFS achieved following platinum-based first-line therapy -- -- This patient also achieved 84.6% reduction in target lesion size, as previously reported by Genelux , exceeding the reduction achieved following first-line therapy --
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Olvi-Vec systemic development programs continue to advance, with additional dose-escalation updates anticipated in 2026 --